Trade TFF Pharmaceuticals, Inc. - TFFP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | N/A |
Open* | 0.38 |
1-Year Change* | -93.48% |
Day's Range* | 0.38 - 0.38 |
52 wk Range | 0.32-6.05 |
Average Volume (10 days) | 83.05K |
Average Volume (3 months) | 3.91M |
Market Cap | 20.94M |
P/E Ratio | -100.00K |
Shares Outstanding | 56.09M |
Revenue | 785.15K |
EPS | -0.87 |
Dividend (Yield %) | N/A |
Beta | 1.17 |
Next Earnings Date | Nov 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 15, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.37 |
Aug 24, 2023 | 0.38 | 0.01 | 2.70% | 0.37 | 0.38 | 0.37 |
Aug 23, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Aug 22, 2023 | 0.39 | 0.01 | 2.63% | 0.38 | 0.39 | 0.38 |
Aug 21, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Aug 16, 2023 | 0.37 | -0.03 | -7.50% | 0.40 | 0.40 | 0.37 |
Aug 15, 2023 | 0.39 | -0.02 | -4.88% | 0.41 | 0.50 | 0.39 |
Aug 14, 2023 | 0.40 | -0.01 | -2.44% | 0.41 | 0.42 | 0.40 |
Aug 11, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.39 | 0.39 |
Aug 8, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Aug 7, 2023 | 0.38 | -0.02 | -5.00% | 0.40 | 0.45 | 0.38 |
Aug 4, 2023 | 0.41 | 0.02 | 5.13% | 0.39 | 0.42 | 0.39 |
Aug 3, 2023 | 0.39 | -0.02 | -4.88% | 0.41 | 0.41 | 0.39 |
Aug 2, 2023 | 0.39 | -0.03 | -7.14% | 0.42 | 0.43 | 0.39 |
Aug 1, 2023 | 0.40 | 0.00 | 0.00% | 0.40 | 0.41 | 0.40 |
Jul 31, 2023 | 0.41 | 0.01 | 2.50% | 0.40 | 0.41 | 0.39 |
Jul 6, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.39 | 0.39 |
Jul 5, 2023 | 0.41 | -0.06 | -12.77% | 0.47 | 0.47 | 0.39 |
Jul 3, 2023 | 0.46 | 0.02 | 4.55% | 0.44 | 0.47 | 0.44 |
Jun 30, 2023 | 0.44 | 0.03 | 7.32% | 0.41 | 0.44 | 0.41 |
TFF Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 13, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 TFF Pharmaceuticals Inc Earnings Release Q3 2023 TFF Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Tuesday, March 5, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 TFF Pharmaceuticals Inc Earnings Release Q4 2023 TFF Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0.49581 | 0.08816 | 0 | 0 | 0 |
Total Operating Expense | 32.2926 | 31.8748 | 18.6936 | 11.9876 | 3.89815 |
Selling/General/Admin. Expenses, Total | 13.7963 | 10.5739 | 8.01209 | 3.16533 | 3.04934 |
Research & Development | 18.4963 | 21.3009 | 10.6816 | 8.82223 | 0.84881 |
Operating Income | -31.7968 | -31.7867 | -18.6936 | -11.9876 | -3.89815 |
Net Income Before Taxes | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
Net Income After Taxes | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
Net Income Before Extra. Items | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
Net Income | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
Income Available to Common Excl. Extra. Items | -31.7701 | -31.0387 | -18.5672 | -36.6753 | -4.57054 |
Income Available to Common Incl. Extra. Items | -31.7701 | -31.0387 | -18.5672 | -36.6753 | -4.57054 |
Diluted Net Income | -31.7701 | -31.0387 | -18.5672 | -36.6753 | -4.57054 |
Diluted Weighted Average Shares | 29.9798 | 24.821 | 20.4252 | 18.451 | 17.8254 |
Diluted EPS Excluding Extraordinary Items | -1.05972 | -1.2505 | -0.90904 | -1.98772 | -0.25641 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -1.05972 | -1.2505 | -0.90904 | -1.98772 | -0.25641 |
Interest Income (Expense), Net Non-Operating | 0.02673 | 0.05123 | 0.12642 | 0.11733 | 0.05596 |
Total Adjustments to Net Income | 0 | -24.8051 | -0.72835 | ||
Revenue | 0.49581 | 0.08816 | |||
Other, Net | 0 | 0.69671 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0.33335 | 0.05143 | 0.31278 | 0.08759 | 0.028 |
Revenue | 0.33335 | 0.05143 | 0.31278 | 0.08759 | 0.028 |
Total Operating Expense | 5.35226 | 7.13788 | 7.69356 | 7.36821 | 8.80082 |
Selling/General/Admin. Expenses, Total | 2.67036 | 3.11922 | 3.55751 | 3.34227 | 3.69001 |
Research & Development | 2.6819 | 4.01866 | 4.13605 | 4.02594 | 5.11081 |
Operating Income | -5.01891 | -7.08645 | -7.38078 | -7.28062 | -8.77282 |
Interest Income (Expense), Net Non-Operating | -0.0013 | 0.03508 | 0.00754 | 0.00612 | 0.00588 |
Other, Net | 0 | 0 | 0.02061 | ||
Net Income Before Taxes | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Net Income After Taxes | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Net Income Before Extra. Items | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Net Income | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Income Available to Common Excl. Extra. Items | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Income Available to Common Incl. Extra. Items | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Diluted Net Income | -5.02021 | -7.05137 | -7.37323 | -7.2745 | -8.74633 |
Diluted Weighted Average Shares | 36.1931 | 36.1931 | 29.9798 | 25.4517 | 25.3737 |
Diluted EPS Excluding Extraordinary Items | -0.13871 | -0.19483 | -0.24594 | -0.28582 | -0.3447 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.13871 | -0.19483 | -0.24594 | -0.28582 | -0.3447 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Liabilities | 1.13066 | 1.96075 | 1.32204 | 0.41064 | 1.157 |
Accounts Payable | 0.91961 | 1.49384 | 1.29773 | 0.41064 | 0.42865 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.24076 | 1.96075 | 1.32204 | 1.54265 | 1.157 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 22.8795 | 38.7371 | 37.3398 | 27.6448 | 9.24451 |
Retained Earnings (Accumulated Deficit) | -97.0884 | -65.3184 | -34.2797 | -15.7124 | -3.84219 |
Total Liabilities & Shareholders’ Equity | 24.1202 | 40.6978 | 38.6618 | 29.1874 | 10.4015 |
Total Common Shares Outstanding | 36.1931 | 25.3718 | 22.5349 | 18.451 | 17.8254 |
Total Current Assets | 19.0252 | 38.838 | 37.559 | 29.1874 | 10.2737 |
Cash and Short Term Investments | 16.6123 | 33.7947 | 35.3008 | 28.0949 | 10.2617 |
Cash & Equivalents | 16.6123 | 33.7947 | 35.3008 | 28.0949 | 10.2617 |
Prepaid Expenses | 2.22634 | 2.44793 | 2.25823 | 1.09246 | 0.01207 |
Total Assets | 24.1202 | 40.6978 | 38.6618 | 29.1874 | 10.4015 |
Other Long Term Assets, Total | 0.00769 | 0 | 0.12777 | ||
Accrued Expenses | 0.08506 | 0.41691 | 0 | 0.72835 | |
Preferred Stock - Non Redeemable, Net | 12.486 | ||||
Common Stock | 0.03619 | 0.02537 | 0.02254 | 0.01845 | 0.004 |
Additional Paid-In Capital | 120.071 | 104.079 | 71.6485 | 43.3387 | 0.59672 |
Other Liabilities, Total | 0.11009 | 0 | 1.13201 | ||
Redeemable Preferred Stock | 0 | ||||
Property/Plant/Equipment, Total - Net | 3.27439 | 1.85986 | 1.10281 | ||
Other Current Liabilities, Total | 0.126 | 0.05 | 0.02432 | ||
Other Equity, Total | -0.1393 | -0.04892 | -0.05154 | ||
Total Receivables, Net | 0.18651 | 2.59535 | |||
Note Receivable - Long Term | 1.81298 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 13.9604 | 19.0252 | 16.979 | 25.1817 | 31.524 |
Cash and Short Term Investments | 12.2164 | 16.6123 | 13.1471 | 20.8902 | 26.4142 |
Cash & Equivalents | 12.2164 | 16.6123 | 13.1471 | 20.8902 | 26.4142 |
Prepaid Expenses | 1.55531 | 2.22634 | 1.06976 | 1.48395 | 2.16445 |
Total Assets | 18.2117 | 24.1202 | 20.2274 | 27.9132 | 33.7828 |
Property/Plant/Equipment, Total - Net | 2.40387 | 3.27439 | 3.24073 | 2.56439 | 2.25874 |
Total Current Liabilities | 1.57684 | 1.13066 | 2.07657 | 3.82751 | 2.19678 |
Accounts Payable | 1.34443 | 0.91961 | 1.63402 | 3.48046 | 2.02878 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.151 | 0.126 | 0.36271 | 0.268 | 0.168 |
Total Liabilities | 1.66837 | 1.24076 | 2.20489 | 3.9737 | 2.19678 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 16.5433 | 22.8795 | 18.0225 | 23.9395 | 31.586 |
Common Stock | 0.03619 | 0.03619 | 0.02552 | 0.02537 | 0.02537 |
Additional Paid-In Capital | 120.805 | 120.071 | 107.923 | 106.462 | 105.257 |
Retained Earnings (Accumulated Deficit) | -104.14 | -97.0884 | -89.7152 | -82.4407 | -73.6944 |
Other Equity, Total | -0.15796 | -0.1393 | -0.21035 | -0.10712 | -0.00169 |
Total Liabilities & Shareholders’ Equity | 18.2117 | 24.1202 | 20.2274 | 27.9132 | 33.7828 |
Total Common Shares Outstanding | 36.1931 | 36.1931 | 25.5181 | 25.3738 | 25.3718 |
Total Receivables, Net | 0.18877 | 0.18651 | 2.76214 | 2.80752 | 2.94541 |
Accrued Expenses | 0.08141 | 0.08506 | 0.07984 | 0.07905 | 0 |
Other Long Term Assets, Total | 0.00769 | 0.00769 | 0.00769 | 0.16708 | |
Other Liabilities, Total | 0.09152 | 0.11009 | 0.12831 | 0.14619 | |
Note Receivable - Long Term | 1.83969 | 1.81298 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -31.7701 | -31.0387 | -18.5672 | -11.8702 | -3.84219 |
Cash From Operating Activities | -27.3422 | -29.557 | -16.6156 | -11.2161 | -2.12699 |
Changes in Working Capital | -0.55108 | -1.59719 | -0.25982 | 0.06407 | 0.38612 |
Cash From Investing Activities | -1.55133 | -0.86851 | -1.10281 | 0 | 0 |
Other Investing Cash Flow Items, Total | 0 | 0 | |||
Cash From Financing Activities | 11.751 | 28.885 | 24.9947 | 29.0494 | 12.3887 |
Financing Cash Flow Items | 0 | -0.09731 | |||
Net Change in Cash | -17.1824 | -1.50613 | 7.20587 | 17.8333 | 10.2617 |
Non-Cash Items | 4.59076 | 2.96748 | 2.21146 | 0.59004 | 1.32907 |
Issuance (Retirement) of Stock, Net | 11.751 | 28.885 | 24.9947 | 29.0494 | 12.486 |
Cash From Operating Activities | 0.38822 | 0.11145 | 0 | ||
Capital Expenditures | -1.55133 | -0.86851 | -1.10281 | ||
Foreign Exchange Effects | -0.03987 | 0.03436 | -0.0704 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -7.05137 | -31.7701 | -24.3968 | -17.1223 | -8.376 |
Cash From Operating Activities | -4.36578 | -27.3422 | -19.6402 | -12.2607 | -7.2463 |
Cash From Operating Activities | 0.12317 | 0.38822 | 0.26731 | 0.16617 | 0.07703 |
Non-Cash Items | 1.44312 | 4.59076 | 2.80813 | 1.87762 | 0.6527 |
Changes in Working Capital | 1.1193 | -0.55108 | 1.68119 | 2.81779 | 0.39998 |
Cash From Investing Activities | 0 | -1.55133 | -1.41016 | -0.63268 | -0.13723 |
Capital Expenditures | 0 | -1.55133 | -1.41016 | -0.63268 | -0.13723 |
Cash From Financing Activities | -0.01792 | 11.751 | 0.41474 | -0.016 | 0 |
Issuance (Retirement) of Stock, Net | 11.751 | 0.41474 | 0.01019 | 0 | |
Foreign Exchange Effects | -0.01225 | -0.03987 | -0.01197 | 0.00501 | 0.00303 |
Net Change in Cash | -4.39596 | -17.1824 | -20.6476 | -12.9044 | -7.3805 |
Financing Cash Flow Items | -0.01792 | -0.02618 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
TFF Pharmaceuticals, Inc. Company profile
About TFF Pharmaceuticals Inc
TFF Pharmaceuticals, Inc. is an early stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. It is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. It is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.
Financial summary
BRIEF: For the nine months ended 30 September 2021, TFF Pharmaceuticals Inc revenues increased from $0K to $76K. Net loss increased 66% to $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $2.8M to $14.1M (expense), Stock-based Compensation in SGA increase of 98% to $2.4M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
2600 Via Fortuna Ste 360
AUSTIN
TEXAS 78746-7983
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com